Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin

No abstract is available for this paper.

• Publication year

  2000

• Venue

  British Journal of Ophthalmology

• Publication date

  2000-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/BJO.84.7.788PMID 10873996PMCID PMC1723565
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Concentric Contraction of the Visual Field in Patients with Temporal Lobe Epilepsy and Its Association with the Use of Vigabatrin Medication

  2000cited by this paper
• Guides to the evaluation of permanent impairment

  2000cited by this paper
• Reversibility of vigabatrin-induced visual-field defect

  1999cited by this paper
• Characteristics of a Unique Visual Field Defect Attributed to Vigabatrin

  1999cited by this paper
• Visual field defects associated with vigabatrin therapy

  1999cited by this paper
• Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

  1999cited by this paper
• Severe persistent visual field constriction associated with vigabatrin

  1998cited by this paper
• Measuring performance in the NHS

  1998cited by this paper
• Study is needed of visual field defects associated with any long term antiepileptic drug

  1998cited by this paper
• Vigabatrin-associated retinal cone system dysfunction

  1998cited by this paper
• ECT should be treatment option in all cases of refractory depression

  1998cited by this paper
• Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.

  1998cited by this paper
• Untersuchungsstrategien bei Simulation und funktionellen Sehstörungen

  1997cited by this paper
• Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.

  1997cited by this paper
• [Examination strategies in simulation and functional vision disorders].

  1997cited by this paper
• Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.

  1997cited by this paper
• Severe persistent visual field constriction associated with vigabatrin

  1997cited by this paper
• Electroculography, ERGs, multifocal ERGs and VEPs in epileptic patients showing visual field disorders

  1997cited by this paper
• Cardiac sarcoidosis

  1997cited by this paper
• Fields of Dreamers and Dreamed-up Fields. Functional and Fake Perimetry

  1996cited by this paper
• Field of dreamers and dreamed-up fields: functional and fake perimetry.

  1996cited by this paper
• Automated perimetry and malingerers. Can the Humphrey be outwitted?

  1995cited by this paper
• Guides to the Evaluation of Permanent Impairment

  1994cited by this paper
• Grids for Functional Scoring of Visual Fields

  1981cited by this paper

• Machine-learning algorithms for the identification of visual field loss associated with the antiseizure medication vigabatrin—a proof of concept

  2025cites this paper
• Visual electrophysiology in the assessment of toxicity and deficiency states affecting the visual system

  2021cites this paper
• OV329, a novel highly potent γ‐aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala‐kindled rats

  2021cites this paper
• Adverse ocular effects to systemic drug therapy

  2020cites this paper
• Szisztémás gyógyszerek szemészeti mellékhatásai

  2020cites this paper
• Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy

  2019cites this paper
• the identification

  2019cites this paper
• Vigabatrin: Lessons Learned From the United States Experience

  2017cites this paper
• Eye Findings on Vigabatrin and Taurine Treatment in Two Patients with Succinic Semialdehyde Dehydrogenase Deficiency

  2016cites this paper
• Electroretinographic Responses in Epileptic Children Treated With Vigabatrin

  2014cites this paper
• Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin?

  2014cites this paper
• Evolution of visual field loss over ten years in individuals taking vigabatrin.

  2013cites this paper
• Patterns of peripapillary retinal nerve fiber layer thinning in vigabatrin-exposed individuals.

  2012cites this paper
• Vigabatrin

  2011cites this paper
• Peripapillary retinal nerve fibre layer thickness in individuals with epilepsy exposed to vigabatrin

  2011cites this paper
• New Antiepileptic Drugs: Lacosamide, Rufinamide, and Vigabatrin

  2010cites this paper
• Epilepsy New Antiepileptic Drugs : Lacosamide , Rufinamide , and Vigabatrin

  2010cites this paper
• Treatment of refractory complex partial seizures: role of vigabatrin

  2009cites this paper
• Treatment of refractory complex partial seizures: role of vigabatrin

  2009cites this paper
• Justification of vigabatrin administration in West syndrome patients? Warranting a re-consideration for improvement in their quality of life.

  2009cites this paper
• Study of visual field defects in patients with epilepsy receiving Vigabatrin

  2009cites this paper
• Vigabatrin: 2008 Update

  2009cites this paper
• The ocular side effects of vigabatrin (Sabril): information and guidance for screening

  2008cites this paper
• Vigabatrin in pediatric patients with refractory epilepsy.

  2006cites this paper
• Vigabatrin and Visual Field Defects in Pediatric Epilepsy Patients

  2006cites this paper
• Drugs and the retina.

  2004cites this paper
• Acute Vigabatrin Retinotoxicity in Albino Rats Depends on Light But Not GABA

  2004cites this paper
• Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship.

  2004cites this paper
• Drugs and the retina

  2004cites this paper
• Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.

  2003cites this paper
• Characterization of vigabatrin-associated optic atrophy.

  2003cites this paper
• Retinal function abnormalities in patients treated with vigabatrin.

  2003cites this paper
• Vigabatrin: longterm follow-up of electrophysiology and visual field examinations.

  2003cites this paper
• Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal

  2002cites this paper
• Neurotoxic effects of GABA‐transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance

  2002cites this paper
• Vigabatrin and retinal changes

  2002cites this paper
• Detection of visual field defects in patients after anterior temporal lobectomy for mesial temporal sclerosis—establishing eligibility to drive

  2002cites this paper
• Visual Field Constriction in 91 Finnish Children Treated with Vigabatrin

  2002cites this paper
• Electro-ophthalmological recovery after withdrawal from vigabatrin

  2002cites this paper
• Patients Treated with Vigabatrin Exhibit Central Visual Function Loss

  2002cites this paper
• Driving after epilepsy surgery: effects of visual field defects and epilepsy control

  2002cites this paper
• Visual field and electrophysiological abnormalities due to vigabatrin

  2002cites this paper
• Effects of antiepileptic drugs on visual function, with special reference to Vigabatrin.

  2002cites this paper
• Visual Field Defects and Other Ophthalmological Disturbances Associated with Vigabatrin

  2001cites this paper
• No reversion in vigabatrin-associated visual field defects

  2001cites this paper
• Rapid development of visual field defects associated with vigabatrin therapy

  2001cites this paper
• Visual Field Defects with Vigabatrin

  2001cites this paper
• Visual Field Loss Associated with Vigabatrin: Quantification and Relation to Dosage

  2001cites this paper
• The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss.

  2001cites this paper
• Visual Field Loss Associated with Vigabatrin: Quantification and Relation to Dosage

  2001cites this paper